Invesco Ltd. Sage Therapeutics, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 87,899 shares of SAGE stock, worth $503,661. This represents 0.0% of its overall portfolio holdings.

Number of Shares

87,899

Previous 661,122 86.7%

Holding current value

$503,661

Previous $7.18 Million 91.18%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$7.02 - $13.08 $4.02 Million - $7.5 Million	-573,223 Reduced 86.7%	87,899 $633,000
Q2 2024 Aug 13, 2024	BUY	$10.58 - $17.9 $6.09 Million - $10.3 Million	575,583 Added 672.89%	661,122 $7.18 Million
Q1 2024 May 14, 2024	BUY	$18.62 - $26.95 $400,013 - $578,966	21,483 Added 33.54%	85,539 $1.6 Million
Q4 2023 Feb 12, 2024	SELL	$17.1 - $22.26 $37,431 - $48,727	-2,189 Reduced 3.3%	64,056 $1.39 Million
Q3 2023 Nov 13, 2023	SELL	$16.75 - $48.98 $732,963 - $2.14 Million	-43,759 Reduced 39.78%	66,245 $1.36 Million
Q2 2023 Aug 11, 2023	BUY	$40.65 - $59.54 $2.08 Million - $3.04 Million	51,104 Added 86.76%	110,004 $5.17 Million
Q1 2023 May 12, 2023	SELL	$37.27 - $46.57 $1.06 Million - $1.32 Million	-28,400 Reduced 32.53%	58,900 $2.47 Million
Q4 2022 Feb 13, 2023	BUY	$32.2 - $43.61 $64,142 - $86,871	1,992 Added 2.34%	87,300 $3.33 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $62,784 - $84,160	-1,945 Reduced 2.23%	85,308 $3.34 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $532,236 - $734,726	-19,340 Reduced 18.14%	87,253 $2.82 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $1.49 Million - $2.21 Million	48,408 Added 83.2%	106,593 $3.53 Million
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $2.53 Million - $3.22 Million	-68,292 Reduced 54.0%	58,185 $2.48 Million
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $17.3 Million - $24.7 Million	-429,727 Reduced 77.26%	126,477 $5.6 Million
Q2 2021 Aug 17, 2021	SELL	$54.88 - $79.29 $51.1 Million - $73.9 Million	-931,613 Reduced 62.62%	556,204 $31.6 Million
Q1 2021 May 17, 2021	BUY	$70.65 - $96.76 $227,775 - $311,954	3,224 Added 0.22%	1,487,817 $111 Million
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $601,214 - $916,694	-10,293 Reduced 0.69%	1,484,593 $128 Million
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $10 Million - $15.2 Million	-243,522 Reduced 14.01%	1,494,886 $91.4 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $628,067 - $1.04 Million	-24,203 Reduced 1.37%	1,738,408 $72.3 Million
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $6.72 Million - $19.8 Million	-256,945 Reduced 12.72%	1,762,611 $50.6 Million
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $11.3 Million - $29.1 Million	187,763 Added 10.25%	2,019,556 $146 Million
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $26.7 Million - $36.1 Million	-190,171 Reduced 9.41%	1,831,793 $257 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $212 Million - $246 Million	1,341,720 Added 197.24%	2,021,964 $370 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $4.03 Million - $7.38 Million	45,095 Added 7.1%	680,244 $108 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $52 Million - $88.7 Million	635,149 New	635,149 $60.8 Million

Others Institutions Holding SAGE

# of Institutions

218

Shares Held

46.4M

Call Options Held

847K

Put Options Held

188K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account